Background: This review describes in chronological order the different assays for hepatitis C virus (HCV) antibodies, for the core antigen and for the HCV-RNA.

Methods: By ascending chronological order, the enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDTs), HCV-Ab IgG avidity index (HCV AI), and Cy3-labeled microarray assay have been described for HCV antibodies in addition to ELISA for the total HCV core antigen (Ag).

Results: The recombinant immunoblot assay (RIBA) is a confirmatory test for HCV-Ab in blood, which is no longer needed due to the use of the sensitive third and fourth generation ELISA in addition to HCV-RNA detection by the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). ELISA and RIBA measure current and prior exposure to HCV infection, but cannot discriminate between the two. RT-PCR is performed after ELISA for the diagnosis of HCV infection whether acute, chronic, false positive or false negative ELISA.

Conclusions: The cooperation between ELISA and RT-PCR in the diagnosis of HCV infection has been tabulated and discussed. HCV genotyping and subtyping testing is essential in pre-treatment evaluation of the patients for setting valuable treatment strategies and in understanding the epidemiology of the virus.

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2016.161113DOI Listing

Publication Analysis

Top Keywords

hcv infection
12
chronological order
8
hcv
8
hcv antibodies
8
core antigen
8
diagnosis hcv
8
elisa
6
hepatitis overview
4
overview laboratory
4
laboratory assays
4

Similar Publications

Early detection of hepatitis C virus (HCV) infection is crucial for eliminating this silent killer, especially in resource-limited settings. HCV core antigen (HCVcAg) represents a promising alternative to the current "gold standard" HCV RNA assays as an active viremia biomarker. Herein, a highly sensitive electrochemical magneto-immunosensor for the HCVcAg was developed.

View Article and Find Full Text PDF

Introduction: The coexistence of gallbladder (LSG) and adenomyomatosis (ADM) is extremely uncommon presenting a novel clinical dilemma that has not been previously documented. LSG refers to a anomaly where the gallbladder is situated to the left of the round ligament deviating from its usual position. This anomaly is rare, with reported occurrences ranging between 0.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally due to HCC late diagnosis and limited treatment options. MiRNAs (miRNAs) emerged as potential biomarkers for various diseases, including HCC. However, the value of miRNA-101 as a serum biomarker for HCV-induced HCC has not been fully investigated.

View Article and Find Full Text PDF

Leveraging Old Hepatitis C Therapies.

N Engl J Med

December 2024

From West Virginia University College of Law, Morgantown (S.S.T.), the Institute of Human Virology, University of Maryland School of Medicine, Baltimore (S.K.), and the Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City (T.J.M.).

View Article and Find Full Text PDF

[Exploring the mechanism of HIV infection on T lymphocyte mitochondrial damage based on MAPK pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

December 2024

Department of Infection and Immunology, Changsha First Hospital, Changsha 410005, China.

Objective To clarify the mechanism that HIV infection mediates mitochondrial damage of CD4 T lymphocytes (CD4 T cells) through mitogen-activated protein kinase (MAPK) pathway. Methods From October 1st, 2022 to March 31st, 2023, 47 HIV-infected people who received antiretroviral therapy (ART) for 4 years were recruited, including 22 immune non-responders (INR) and 25 responders (IR); and 26 sex and age-matched control participants (HC) who were negative for HCV, HBV, and HIV infections. The immune parameters were analyzed by flow cytometry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!